Regulation of MMP-9 by p53 in first trimester cytotrophoblastic cells

Human Reproduction

Volumn 23, Issue 10, 2008, Pages 2273-2281

  Cohen, M ^a   Wuillemin, C ^a   Irion, O ^a   Bischof, P ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

First trimester cytotrophoblast; Gelatinase; Matrix metalloproteinase 2; Matrix metalloproteinase 9; p53

Indexed keywords

ETOPOSIDE; GELATINASE A; GELATINASE B; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; CYTOTROPHOBLAST; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR WEIGHT; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TROPHOBLAST;

EID: 52449112175     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den264     Document Type: Article

References (48)

1. Ala-aho R, Grénman R, Seth P, Kähäri VM. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 2002;21:1187-1195.
2. Backstrom JR, Lim GP, Cullen MJ, Tökés ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996;16:7910-7919.
3. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-915.
4. Behrendsten O, Werb Z. Metalloproteinases regulate parietal endoderm differentiating and migrating in cultured mouse embryos. Dev Dyn 1997;208:255-265.
5. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-6338.
6. Bischof P, Friedli E, Martelli M, Campana A. Expression of extracellular matrix-degrading metalloproteinases by cultured human cytotrophoblast cells: effects of cell adhesion and immunopurification. Am J Obstet Gynecol 1991;165:1791-1801.
7. Bischof P, Martelli M, Campana A, Itoh Y, Ogata Y, Nagase H. Importance of matrix metalloproteinases in human trophoblast invasion. Early Pregnancy 1995;1:263-269.
8. Bischof P, Truong K, Campana A. Regulation of trophoblastic gelatinases by proto-oncogenes. Placenta 2003;24:155-163.
9. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-2137.
10. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-S43.
11. Cohen M, Meisser A, Bischof P. Metalloproteinases and Human Placental Invasiveness. Placenta 2006;27:783-793.
12. Cohen M, Meisser A, Haenggeli L, Irminger-Finger I, Bischof P. Status of p53 in cytotrophoblastic cells. Mol Hum Reprod 2007;13:111-116.
13. Cowland JB, Borregaard N. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukoc Biol 1999;66:989-995.
14. Donehower LA, Bradley H. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205.
15. El-Deiry WS, Kern S, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-49.
16. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
17. Giraudon P, Vernant JC, Confavreux C, Belin MF, Desgranges C. Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology 1998;50:1920.
18. Haidacher S, Blaschitz A, Desoye G, Dohr G. Immunohistochemical evidence of p53 protein in human placenta and choriocarcinoma cell lines. Hum Reprod 1995;10:983-988.
19. Hurskainen T, Hoyhtya M, Tuttila A, Oikarinen A, Autio-Harmainen H. mRNA expressions of TIMP-1, -2, and -3 and 92-KD type IV collagenase in early human placenta and decidual membrane as studied by in situ hybridisation. J Histochem Cytochem 1996;44:1379-1388.
20. Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H, Suzuki Y, Li YF, Takayama M. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003;24:53-64.
21. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-823.
22. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-1737.
23. Kuzuya M, Iguchi A. Role of matrix metalloproteinases in vascular remodelling. J Atheroscler Thromb 2003;10:275-282.
24. Librach CL, Werb Z, Fitzgerald ML, Chiu K, Corwin NM, Esteves RA, Grobelny D, Galardy R, Damsky CH, Fisher SJ. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol 1991;113:437-449.
25. Liu J, Zhan M, Hannay JAF, Das R, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-κB-induced matrix metalloproteinase-9 promotor activation: Implications of soft tissue sarcoma growth and metastasis. Mol Cancer Res 2006;4:803-810.
26. Martelli M, Campana A, Bischof P. Secretion of matrix metalloproteinases by human endometrial cells in vitro. J Reprod Fertil 1993;98:67- 76.
27. Marzusch K, Ruck P, Horny HP, Dietl J, Kaiserling E. Expression of the p53 tumour suppressor gene in human placenta: an immunohistochemical study. Placenta 1995;16:101-104.
28. Meisser A, Chardonnens D, Campana A, Bischof P. Effects of tumour necrosis factor-alpha, interleukin-1 alpha, macrophage colony stimulating factor and transforming growth factor beta on trophoblastic matrix metalloproteinases. Mol Hum Reprod 1999;5:252-260.
29. Meyer E, Vollmer JY, Bovey R, Stamenkovic I. Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 2005;65:4261-4272.
30. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
31. Nikolaev M, Li N, Puskas J, Gu QW. Parc A cytoplasmic anchor for p53. Cell 2003;112:29-40A.
32. O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat 2003;6:313-322.
33. Polette M, Nawrocki B, Pintiaux A, Massenat C, Maquoi E, Volders L, Schaaps JP, Birembaut P, Foidart JM. Expression of gelatinases A and B and their tissue inhibitors by cells of early and term human placenta and gestational endometrium. Lab Invest 1994;71:838-846.
34. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004;49:179-186.
35. Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher SJ. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004;114:744-754.
36. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
37. Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T, Yagel S. Developmental regulation of the expression of 72 and 92 kD type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am J Obstet Gynecol 1994;171:832-838.
38. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Comm 2005;331:834-842.
39. Staun-Ram E, Goldman S, Gabarin D, Shalev E. Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion. Reprod Biol Endocrinol 2004;2:59.
40. Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol 1992;66:4757-4762.
41. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 1999;274:11535-11540.
42. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, Howell DS, Cheung HS. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000;275:11327-11332.
43. Sun Y, Zeng XR, Wenger L, Firestein GS, Cheung HS. P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 2004;92:258-269.
44. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536.
45. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123-2133.
46. Werner H, Karnieli E, Rauscher F, Leroith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996;93:8318-8323.
47. Xu P, Wang YL, Zhu SJ, Luo SY, Piao YS, Zhuang LZ. Expression of matrix metalloproteinase-2, -9, and -14, tissue inhibitors of metalloproteinase-1, and matrix proteins in human placenta during the first trimester. Biol Reprod 2000;62:988-994.
48. Zaika A, Marchenko N, Moll UM. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 1999;274:27474-27480.